INCY vs ZBH: fair value comparison
Incyte Corporation and Zimmer Biomet Holdings, Inc. · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, INCY currently sits closer to the top of our discount ranking. INCY carries the stronger quality grade. INCY carries the stronger momentum grade.
| INCY | ZBH | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $124.37 | $100.91 |
| 12-month range | $85.98–$119.52 | $82.90–$105.01 |
| Sector rank | #35 of 113 Healthcare | #40 of 113 Healthcare |
| Quality grade | A | B |
| Momentum grade | A | B |
| Leverage | Low | Moderate |
| Margin trend | Stable | Stable |
| Revenue growth | Strong | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | — |
| DCF cross-check | Overvalued | Undervalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: INCY fair value analysis · ZBH fair value analysis